ClinicalTrials.Veeva

Menu

Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage

Johns Hopkins University logo

Johns Hopkins University

Status and phase

Terminated
Phase 3
Phase 2

Conditions

Headaches Associated With Subarachnoid Hemorrhage (SAH)

Treatments

Drug: Low dose fentanyl PCA
Drug: Standard IV fentanyl bolus

Study type

Interventional

Funder types

Other

Identifiers

NCT01851720
NA_00071159

Details and patient eligibility

About

Headaches associated with subarachnoid hemorrhage (SAH) cause severe pain. Headache management is complex, requiring a balance between pain control and preservation of neurological assessment. Sufficient pain control can be achieved with narcotics, however, these carry numerous undesirable side effects. Most critically, all narcotics can result in respiratory depression and sedation. For patients who present without neurological defects but debilitating pain, management is particularly challenging. The sedative effect of narcotics confounds the management of these patients by interfering with the neurological examination. Pain management is also a significant concern for patient's families as they observe suffering without full understanding of the importance of preserved mental status. In order to control the pain associated with SAH headaches, the use of narcotics is often required despite the risks. This standard therapy involves an IV bolus dose delivered by the provider regularly as needed for pain control. A common approach to reduce pain in other patient populations, including acute pain relief following major spine surgery, is patient controlled analgesia (PCA). With the PCA method, patients deliver low doses of narcotics through a pain pump with preset maximal doses and frequency of delivery. We hypothesize that this approach to pain relief for SAH headaches will result in lower pain scores, greater patient and family satisfaction scores, and increased patient safety with lower narcotic doses minimally interfering with neurological assessment.

Enrollment

1 patient

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age>18-75
  • Glasgow Coma Scale (GCS) 13 or greater
  • Hunt and Hess grade I, II conditions
  • Admitted within 2 days of initial SAH event >6/10 pain on presentation

Exclusion criteria

  • Aphasia
  • Head trauma within the past 30 days
  • Need for craniotomy
  • h/o obstructive sleep apnea or respiratory disease
  • h/o opioid tolerance
  • evidence of vasospasm
  • h/o liver disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

1 participants in 2 patient groups

Control group / Standard of Care
Active Comparator group
Description:
* IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain * (Bolus dose can be titrated up in 25 mcg increments if necessary) * Maximum dose of 100 mcg/hr
Treatment:
Drug: Standard IV fentanyl bolus
Low dose IV fentanyl PCA
Active Comparator group
Description:
* Initially: 10 mcg demand dose every 12 minutes * No initial bolus and no continuous infusion * Demand dose increased 10 mcg every 12 minutes if necessary * Maximum dose of 100 mcg/hr
Treatment:
Drug: Low dose fentanyl PCA

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems